Riskpilot← Back to searchSign inGet full accessNeobiomics AB
ABActiveOrg 5590722186Fogdevreten 2 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20165-9 employees
Revenue 2024
SEK 15,8M
+38% vs 2023
EBITDA margin
24.7%
+5556% vs 2023
Equity ratio
89.4%
Financial strength
Net profit 2024
SEK 3,8M
+6833% vs 2023
| Revenue | SEK 15,8M | +38% |
| EBITDA | SEK 3,9M | +5556% |
| Net profit | SEK 3,8M | +6833% |
| Total assets | SEK 10,4M | +17% |
| Equity | SEK 9,3M | +69% |
| Employees | — | — |
Legal name
Neobiomics AB
Org number
5590722186
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 augusti 2016
Share capital
SEK 535 756
Employees
5-9
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Utveckling och försäljning av kosttillskott, partihandel med läkemedel, samt därmed förenlig verksamhet.
Address
Fogdevreten 2 A
Email
info@neobiomics.eu
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 95 | 1 234 | 4 006 | 8 876 | 11 440 | 15 834 |
| Staff expenses | — | — | — | — | — | — | −3 856 | −6 002 |
| EBITDA | −18 | −71 | −654 | −8 992 | −1 938 | 1 019 | 69 | 3 909 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −4 | −27 |
| EBIT | −18 | −71 | −654 | −8 992 | −1 938 | 1 019 | 65 | 3 882 |
| Net financials | — | — | −36 | −94 | −77 | −83 | −121 | −66 |
| Profit before tax | −18 | −71 | −690 | −9 086 | −2 015 | 936 | −57 | 3 816 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −18 | −71 | −690 | −9 086 | −2 015 | 936 | −57 | 3 816 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 32 | 279 | 6 421 | 1 684 | 6 113 | 8 793 | 8 889 | 10 379 |
| Equity | 32 | 279 | 5 213 | −2 265 | 2 033 | 5 540 | 5 484 | 9 281 |
| Long-term debt | 0 | 0 | 1 200 | 841 | 562 | 1 080 | 347 | 36 |
| Short-term debt | 0 | 0 | 8 | 3 108 | 3 518 | 2 172 | 3 058 | 1 061 |
| Total debt | — | — | 1 208 | 3 949 | 4 080 | 3 252 | 3 405 | 1 097 |
EBITDA margin
24.7%
This company
15.8%
Market median
+56% vs market
20172024
Equity ratio
89.4%
This company
38.2%
Market median
+134% vs market
20172024
Return on equity
41.1%
This company
18.4%
Market median
+123% vs market
20172024
Net profit margin
24.1%
This company
8.1%
Market median
+198% vs market
20172024
Asset turnover
1.53×
This company
1.12×
Market median
+37% vs market
20172024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-08-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CG Chief Auditor | Chief Auditor | 2022 | — | — |
SM Chief Auditor | Chief Auditor | 2022 | — | — |
ES Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
FM Chief Auditor | Chief Auditor | 2020 | — | — |
CG Chief Auditor | Chief Auditor | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Neobiomics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Gustaf Håkan Ehrs | Chief Auditor | 0 companies |
| Sara Maria Charlotta Wallinder | Chief Auditor | 0 companies |
| Emma Sofia Mårtensson Höglund | Chief Executive Officer | 0 companies |
| Fatima Masic | Chief Auditor | 0 companies |
| Carl Gustaf Håkan Ehrs | Chief Auditor | 0 companies |
| Britt Ann-Charlotte Beckman | Board of Directors | 0 companies |
| Inger Kristina Magnusson Borg | Board of Directors | 0 companies |
| Gustav Stefan Johansson | Chairman | 0 companies |
| Carl Staffan Thunell | Chairman | 0 companies |
| Jens David Sandström | Board of Directors | 0 companies |
| Dan Mårten Österlund | Board of Directors | 0 companies |
| Philipp Novak | Board of Directors | 0 companies |